ARKG ARK Genomic Revolution ETF Loading... : Investor Sentiment and Bull/Bear Views

Loading chart...
Top Calls

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
Time Author Thesis Company / ticker Signal Since call Position Source
02:36
Oct 21
Long ARKG into Anthropic IPO roadshow
Goes long ARKG into Anthropic's IPO roadshow, arguing that if Anthropic is valued at $1.8 trillion investors may pay $20 billion for a biotech play as the non-inference narrative builds.
ARKG ARK Genomic Revolution ETF Long 1ST — —
11:55
Oct 17
Chesley Investment Advisory
Buy ARKG for biotech cycle.
Park argued that falling US rates should bring money back to biotech, and ARKG holds attractive gene-sequencing, liquid-biopsy and AI-healthcare companies. He suggested investors could simply buy ARKG with a 10-year horizon and split purchases, while noting Cathie Wood's venture-style management as a caveat.
ARKG ARK Genomic Revolution ETF Long 1ST — —
17:09
Oct 12
ARKG to outperform ETFs over months
Expects biotech to do well in Q4 and thinks ARKG will outperform many ETFs over coming months despite being red today.
ARKG ARK Genomic Revolution ETF Long — —
Log in to see ideas

About ARKG Investor Commentary

Across the available history and selected sources, Buzzberg tracks ARKG (ARK Genomic Revolution ETF) across 18 sources: 35 bullish vs 1 bearish calls from 14 authors. Historical directional balance: 55% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 62 total trade ideas tracked. Past 7 days, before deduplication: 2 bullish, 3 other directions. Latest voices: Alexander Good, Park Se-ik, wliang.